SpeeDx Pty Ltd published an evaluation comparing the high-throughput RespiV PlexPlus multiplex assay to BioFire Respiratory Panel 2.1 plus.
Published
Signal category
Research & Knowledge
Quote
“Evaluation of the high-throughput RespiV PlexPlus® multiplex assay compared to BioFire® Respiratory Panel 2.1 plus”
— SpeeDx Pty Ltd team
Company
SpeeDx Pty Ltd
Empowering clinicians to make informed treatment decisions.
- Industry
- Biotechnology Research
- Location
- Eveleigh, AU
- Company size
- 84 employees
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
Founded 2009